7 of 10 r/r NHL patients achieved complete response (70% CR rate) following treatment with NKX019 monotherapy at 1 billion…
- Data updates at EAACI 2023 continue to position barzolvolimab as a potential best-in-class addition to a historically limited treatment…
Data on CD19/BCMA dual-targeting FasTCAR-T GC012F showed 100% overall response rate (ORR) and 66.7% 6-month complete response (CR) rate among…
The COMMODORE 2 study demonstrated that subcutaneous crovalimab every four weeks was non-inferior to intravenous eculizumab every two weeks, with…
– Data demonstrates Notable’s PPMP potential in selecting more active investigational pre-hematopoietic stem cell therapy drug combinations, as compared to…
“The Progression of Surgical Robotics: Introducing the SSi Mantra System” Video Presentation Now Available for Viewing FORT LAUDERDALE, FL, June…
MINNEAPOLIS, June 09, 2023 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on…
SAN DIEGO, June 09, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced…
Governor Polis to kick off the world's largest gathering of the psychedelic ecosystem in DenverDENVER, June 09, 2023 (GLOBE NEWSWIRE)…
Endocrine Society President to Present Crinetics CEO with John D. Baxter Prize for EntrepreneurshipSAN DIEGO, June 09, 2023 (GLOBE NEWSWIRE)…